Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma ...
Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025Executing on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback